{"id":22106,"date":"2025-04-29T17:06:19","date_gmt":"2025-04-29T10:06:19","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=22106"},"modified":"2025-04-29T17:06:19","modified_gmt":"2025-04-29T10:06:19","slug":"bpipo-and-dcb-partner-with-link-j-for-the-first-regenerative-medicine-investment-event-in-tokyo","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=22106","title":{"rendered":"BPIPO and DCB Partner with LINK-J for the First Regenerative Medicine Investment Event in Tokyo"},"content":{"rendered":"

TOKYO<\/span>, April 29, 2025<\/span> \/PRNewswire\/ — The inaugural Taiwan-Japan Investment and Industry Networking Event took place at the Global Life Science Hub in Tokyo. The forum united leading biotech and pharmaceutical companies to explore cross-border investment, technology collaboration, and market growth. Key organizations\u2014including\u00a0BPIPO, DCB, LINK-J, and FIRM\u2014highlighted partnership in regenerative medicine and drug innovation, aiming to bridge Taiwan’s biotech strengths with Japan’s investment and clinical development capabilities.<\/p>\n

\n

\"Strengthening <\/a>
Strengthening Taiwan-Japan ties, seven pioneering biotech companies showcase innovation in regenerative medicine and drug development. Top: Dr. Hong-Lin Su, DuoGenic StemCells Chairman (right), signing a non-exclusive licensing agreement with Japan\u2019s A&I Co., Ltd. Bottom: Pictured from left to right are Dr. Shuen-iu Hung, AngenMed Therapeutics CEO; Mr. Tang Shan Wen, GNT Chairman; Dr. Chih-Chuan Su, LumiSTAR Biotechnology Senior Business Development Manager; Ms. Fiona Tsai, BIONET Therapeutics Special Assistant to the General Manager; Dr. Sung Yuan Chen, HeXun Biosciences Vice General Manager; and Dr. Richard Shieh, Ascension Medical Biotechnology Chairman. Image: GeneOnline.<\/span><\/p>\n<\/div>\n

7 Taiwanese Companies Showcase Regenerative Medicine, Immuno-Oncology, and Precision Healthcare<\/b> <\/p>\n

Mr. Keita Komatsu, Deputy Director of the Bio-Industry Division at Japan’s Ministry of Economy, Trade and Industry (METI), expressed optimism for increased support in regenerative medicine investment programs between Taiwan and Japan. During the event, 6 leading Japanese venture capital firms and 30 pharmaceutical and biotech companies, including\u00a0DCI Partners and Eight Roads Ventures, offered insights and emerging technologies.<\/p>\n

Seven Taiwanese regenerative medicine companies were selected to showcase at the event, including:<\/p>\n

DuoGenic StemCells Corporation<\/b>\u00a0highlighted its stem cell therapies for degenerative diseases. Chairman Hong-Lin Su noted, “Our 3-in-1 solution\u2014platelet-rich fibrin, PBMCs, and growth factors\u2014combines physical and chemical components to control osteoarthritis.” In a similar vein, Ascension Medical Biotechnology Co., Ltd. <\/b>emphasized its integrated GMP manufacturing and clinical trial results. “We can induce over 100 types of exosomes, targeting a range of diseases,” Chairman Dr Richard Shieh explained.<\/p>\n

For cancer care, AngenMed Therapeutics, Inc. <\/b>presented its immuno-oncology therapies for solid tumors. CEO Shuen-iu Hung stated, “We enable precise anti-tumor immunity and long-term surveillance. Integrating clinical services and trials in Japan will accelerate our impact.”<\/p>\n

Meanwhile, GNT Inc.<\/b> showcased its nanotech and dermatology. Chairman Shan-Wen Tang said “GNT.Tec6, a needle-free, supersonic device for painless, non-invasive drug delivery also deliver exosomes hair follicle, promoting hair growth.”<\/p>\n

Similarly, HeXun Biosciences Co., Ltd. <\/b>offers full CDMO services from R&D to GMP production using automated systems. Vice GM Sung Yuan Chen said, “Automation boosts consistency and helps clients speed up development and ensure quality.<\/p>\n

Furthermore, BIONET Therapeutics Corp. <\/b>presented its AI-driven approach to cell therapies and exosome development. “AI streamlines data analysis and treatment optimization,” said Special Assistant Fiona Tsai. “We’re ready to take our exosome platform global.”<\/p>\n

Finally, LumiSTAR Biotechnology, Inc.<\/b> featured its iPSC Regenerative Medicine & Drug Screening Platform. Senior BD Manager Chih-Chuan Su remarked, “The tech may be complex, but the goal\u2014faster drug discovery\u2014is simple.”<\/p>\n

Collectively, these companies highlight Taiwan’s vibrant biotech ecosystem, advancing global healthcare through regenerative medicine, oncology, diagnostics, and AI innovation.<\/p>\n

DuoGenic StemCells and A&I Corporation Enter Licensing Agreement<\/b> <\/p>\n

A key highlight was the signing of a licensing agreement between Taiwan-based DuoGenic StemCells and Japan’s A&I Corporation, facilitated by BPIPO and FIRM. The deal grants A&I rights to DuoGenics’ AI Cells technology, therapeutic approvals, marketing, and sales in Japan, marking a milestone in Taiwan-Japan biotech collaboration.<\/p>\n

The event not only opens new opportunities for biotech companies but also advances a robust biotech ecosystem rooted in cross-border collaboration.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TOKYO<\/span>, April 29, 2025<\/span> \/PRNewswire\/ — The inaugural Taiwan-Japan Investment and Industry Networking Event took place at the Global Life Science Hub in Tokyo. The forum united leading biotech and pharmaceutical companies to explore cross-border investment, technology collaboration, and market growth. Key organizations\u2014including\u00a0BPIPO, DCB, LINK-J, and FIRM\u2014highlighted partnership in regenerative medicine and drug innovation, aiming to bridge Taiwan’s biotech strengths with Japan’s investment and clinical development capabilities.<\/p>\n

\n

\"Strengthening <\/a>
Strengthening Taiwan-Japan ties, seven pioneering biotech companies showcase innovation in regenerative medicine and drug development. Top: Dr. Hong-Lin Su, DuoGenic StemCells Chairman (right), signing a non-exclusive licensing agreement with Japan\u2019s A&I Co., Ltd. Bottom: Pictured from left to right are Dr. Shuen-iu Hung, AngenMed Therapeutics CEO; Mr. Tang Shan Wen, GNT Chairman; Dr. Chih-Chuan Su, LumiSTAR Biotechnology Senior Business Development Manager; Ms. Fiona Tsai, BIONET Therapeutics Special Assistant to the General Manager; Dr. Sung Yuan Chen, HeXun Biosciences Vice General Manager; and Dr. Richard Shieh, Ascension Medical Biotechnology Chairman. Image: GeneOnline.<\/span><\/p>\n<\/div>\n

7 Taiwanese Companies Showcase Regenerative Medicine, Immuno-Oncology, and Precision Healthcare<\/b> <\/p>\n

Mr. Keita Komatsu, Deputy Director of the Bio-Industry Division at Japan’s Ministry of Economy, Trade and Industry (METI), expressed optimism for increased support in regenerative medicine investment programs between Taiwan and Japan. During the event, 6 leading Japanese venture capital firms and 30 pharmaceutical and biotech companies, including\u00a0DCI Partners and Eight Roads Ventures, offered insights and emerging technologies.<\/p>\n

Seven Taiwanese regenerative medicine companies were selected to showcase at the event, including:<\/p>\n

DuoGenic StemCells Corporation<\/b>\u00a0highlighted its stem cell therapies for degenerative diseases. Chairman Hong-Lin Su noted, “Our 3-in-1 solution\u2014platelet-rich fibrin, PBMCs, and growth factors\u2014combines physical and chemical components to control osteoarthritis.” In a similar vein, Ascension Medical Biotechnology Co., Ltd. <\/b>emphasized its integrated GMP manufacturing and clinical trial results. “We can induce over 100 types of exosomes, targeting a range of diseases,” Chairman Dr Richard Shieh explained.<\/p>\n

For cancer care, AngenMed Therapeutics, Inc. <\/b>presented its immuno-oncology therapies for solid tumors. CEO Shuen-iu Hung stated, “We enable precise anti-tumor immunity and long-term surveillance. Integrating clinical services and trials in Japan will accelerate our impact.”<\/p>\n

Meanwhile, GNT Inc.<\/b> showcased its nanotech and dermatology. Chairman Shan-Wen Tang said “GNT.Tec6, a needle-free, supersonic device for painless, non-invasive drug delivery also deliver exosomes hair follicle, promoting hair growth.”<\/p>\n

Similarly, HeXun Biosciences Co., Ltd. <\/b>offers full CDMO services from R&D to GMP production using automated systems. Vice GM Sung Yuan Chen said, “Automation boosts consistency and helps clients speed up development and ensure quality.<\/p>\n

Furthermore, BIONET Therapeutics Corp. <\/b>presented its AI-driven approach to cell therapies and exosome development. “AI streamlines data analysis and treatment optimization,” said Special Assistant Fiona Tsai. “We’re ready to take our exosome platform global.”<\/p>\n

Finally, LumiSTAR Biotechnology, Inc.<\/b> featured its iPSC Regenerative Medicine & Drug Screening Platform. Senior BD Manager Chih-Chuan Su remarked, “The tech may be complex, but the goal\u2014faster drug discovery\u2014is simple.”<\/p>\n

Collectively, these companies highlight Taiwan’s vibrant biotech ecosystem, advancing global healthcare through regenerative medicine, oncology, diagnostics, and AI innovation.<\/p>\n

DuoGenic StemCells and A&I Corporation Enter Licensing Agreement<\/b> <\/p>\n

A key highlight was the signing of a licensing agreement between Taiwan-based DuoGenic StemCells and Japan’s A&I Corporation, facilitated by BPIPO and FIRM. The deal grants A&I rights to DuoGenics’ AI Cells technology, therapeutic approvals, marketing, and sales in Japan, marking a milestone in Taiwan-Japan biotech collaboration.<\/p>\n

The event not only opens new opportunities for biotech companies but also advances a robust biotech ecosystem rooted in cross-border collaboration.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-22106","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/22106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22106"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/22106\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}